Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Effect of PectaSol-C® modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study

Better Health Publishing
Posted on: 19 Jun 17

PR Newswire

SANTA ROSA, Calif., June 15, 2017

SANTA ROSA, Calif., June 15, 2017 /PRNewswire/ -- Interim results from Phase IIb clinical trial showed impressive and promising results in patients with recurrent prostate cancer. The interim results have just been published in the Journal of Clinical Oncology in conjunction with the 2017 ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago, IL. The interim findings of the clinical trial conducted at Meir Medical Center in Kfar-Saba, Israel demonstrated the ability of modified citrus pectin (MCP) to slow the PSA doubling time (PSADT) in prostate cancer patients with non-metastatic biochemical relapse. PSADT is an accurate measurement for recurrent prostate cancer growth in patients whose prostate has been locally targeted with surgery and/or radiation. Patients from multiple cancer centers in Israel were referred to Meir Hospital, where the study was conducted.  As a leading integrative medical news platform, Better Health Publishing works with research institutes worldwide to announce important data highlighting botanical and nutritional adjuncts in the treatment of chronic conditions.

The researchers found that based on PSADT, 79% of patients had a slowing down of their prostate cancer growth, and in 62% of patients the cancer didn't grow or got smaller. The results are reported based on 6 months of data of the first 35 patients enrolled.

"This study confirmed the results seen in two previous smaller studies," Says Dr. Moshe Frenkel, co-investigator of the trial and Clinical Associate Professor at the University of Texas Medical Branch, as well as being the director of the Complementary and Integrative Medicine Unit in the Institute of Oncology in Meir Medical Center. "We are constantly looking for natural options that affect cancer progression with minimal side effects. Based on the intermediary findings of the study, MCP has the potential to fall into this category with patients affected by prostate cancer."

The pectin is extracted from the pith of citrus fruit peels that undergoes a modification process that enables its entrance to the circulation. MCP has diverse indications, from inflammatory and fibrotic diseases that affect multiple organs to cancer and immunity, and has become an increasingly popular essential daily nutritional supplement.

Source: Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/effect-of-pectasol-c-modified-citrus-pectin-p-mcp-treatment-tx-on-psa-dynamics-in-patients-pts-with-nonmetastatic-biochemically-relapsed-prostate-cancer-brpc-results-of-the-interim-analysis-of-a-prospective-phase-ii-stu-300475925.html

SOURCE Better Health Publishing

PR Newswire
www.prnewswire.com

Last updated on: 19/06/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.